Suppr超能文献

[儿童神经纤维瘤病的诊断与治疗进展]

[Progress in diagnosis and treatment of neurofibromatosis in children].

作者信息

Wang Shengcai, Li Yanzhen, Zhang Jie, Ni Xin

机构信息

Department of Otolaryngology Head and Neck Surgery,Beijing Children's Hospital,Capital Medical University,National Center for Children's Health,Beijing Key Laboratory for Pediatric Disease of Otolaryngology Head and Neck Surgery,Beijing,100045,China.

出版信息

Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Jun;36(6):477-482. doi: 10.13201/j.issn.2096-7993.2022.06.015.

Abstract

Neurofibromatosis type 1(NF1) is an autosomal dominant genetic disease in which a mutation in the NF1 gene on chromosome 17q11.2 results in inactivation or down-regulation of neurofibromin. This results in a series of neurocutaneous lesions characterized by neurofibromatosis. Patients with plexiform neurofibromas(PN), as one of the main manifestations of NF1, often experience pain, dysfunction, skeletal deformities, changes in appearance and other symptoms. In severe cases, compression of the airways and vital organs occurs, and the PN is at risk of malignancy progression. At present, its treatment is still challenging. Surgery is the primary treatment for PN, but complete resection is often difficult. In recent years, chemotherapy for PN has become a hot topic. This article reviews the research progress in the pathogenesis, diagnosis and treatment of PN in recent years.

摘要

1型神经纤维瘤病(NF1)是一种常染色体显性遗传病,其中17q11.2染色体上的NF1基因发生突变,导致神经纤维瘤蛋白失活或下调。这会导致一系列以神经纤维瘤病为特征的神经皮肤病变。患有丛状神经纤维瘤(PN)的患者,作为NF1的主要表现之一,常经历疼痛、功能障碍、骨骼畸形、外观改变等症状。在严重情况下,会发生气道和重要器官受压,并且PN有恶性进展的风险。目前,其治疗仍然具有挑战性。手术是PN的主要治疗方法,但往往难以完全切除。近年来,PN的化疗已成为一个热门话题。本文综述了近年来PN在发病机制、诊断和治疗方面的研究进展。

相似文献

1
[Progress in diagnosis and treatment of neurofibromatosis in children].[儿童神经纤维瘤病的诊断与治疗进展]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Jun;36(6):477-482. doi: 10.13201/j.issn.2096-7993.2022.06.015.
7
Neurofibromatosis type 1 (NF1): diagnosis and management.1型神经纤维瘤病(NF1):诊断与管理
Handb Clin Neurol. 2013;115:939-55. doi: 10.1016/B978-0-444-52902-2.00053-9.

本文引用的文献

2
Current status of MEK inhibitors in the treatment of plexiform neurofibromas.MEK抑制剂在丛状神经纤维瘤治疗中的现状
Childs Nerv Syst. 2020 Oct;36(10):2443-2452. doi: 10.1007/s00381-020-04731-2. Epub 2020 Jun 30.
4
Selumetinib: First Approval.色瑞替尼:首次批准。
Drugs. 2020 Jun;80(9):931-937. doi: 10.1007/s40265-020-01331-x.
5
Molecular targets for NF1-associated malignant peripheral nerve sheath tumor.神经纤维瘤病1型相关恶性外周神经鞘膜瘤的分子靶点
Rep Pract Oncol Radiother. 2020 Jul-Aug;25(4):556-561. doi: 10.1016/j.rpor.2020.04.010. Epub 2020 Apr 27.
10
Fluorescein-guided resection of plexiform neurofibromas: how I do it.荧光素引导下丛状神经纤维瘤切除术:我的操作方法。
Acta Neurochir (Wien). 2019 Oct;161(10):2141-2145. doi: 10.1007/s00701-019-04038-5. Epub 2019 Aug 21.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验